Evidence map›Paper›PMID 42635049›Full record

ArticleJCI insight2026

USP10 mitigates Ang II-induced atrial remodeling and atrial fibrillation susceptibility by deubiquitinating NDUFS1.

Wanrong Fu, Xiao-Xu Tian, Jianghua Zhou, Yu-Xu Huang, Huan Li, Zhenya Wang, Tong-You Wade Wei, Li Li, Guo-Jun Zhao

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wanrong FuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiao-Xu TianDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jianghua ZhouDepartment of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yu-Xu HuangDepartment of Medicine, JingGangShan University, Ji'an, China.
Huan LiDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhenya WangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Tong-You Wade WeiDivision of Cardiology, Department of Medicine, UCSD, La Jolla, California, USA.
Li LiDepartment of Cardiovascular Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guo-Jun ZhaoDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atrial fibrillation (AF) contributes to cardiovascular morbidity and mortality. Ubiquitin-specific peptidase 10 (USP10) plays a crucial role in numerous cellular processes; however, its particular role in AF remains largely unexplored. In the present study, USP10 expression was assessed in human atrial samples and angiotensin II-treated (Ang II-treated) mouse atrial tissues. An Ang II-induced AF mouse model was employed to investigate the effects of USP10 on atrial remodeling and AF susceptibility. Calcium imaging and patch clamp techniques were used to evaluate USP10's influence on calcium handling and triggered activity. Additionally, RNA sequencing, coimmunoprecipitation, and ubiquitination assays were performed to explore the regulatory interactions between USP10 and NADH:ubiquinone oxidoreductase subunit S1 (NDUFS1). Our findings demonstrate that USP10 is downregulated in atrial tissues from mouse models and patients with AF. USP10 overexpression counteracts Ang II-induced atrial remodeling and reduces AF susceptibility. Furthermore, USP10 contributes to the restoration of mitochondrial function in AF. Mechanistically, USP10 deubiquitinates NDUFS1 at lysine 621, stabilizing NDUFS1 protein levels and mitigating Ang II-induced mitochondrial dysfunction. This study uncovers a critical mechanistic link between USP10 and NDUFS1. Our findings suggest that upregulating USP10 or targeting NDUFS1 degradation could provide an alternative therapeutic strategy to mitigate AF progression and associated cardiovascular risk.

Indexed as

Angiotensin IIAtrial FibrillationAtrial RemodelingUbiquitin ThiolesteraseAnimalsDisease Models, AnimalFemaleHeart AtriaHumansMaleMiceMice, Inbred C57BLMyocytes, CardiacUbiquitinationAngiotensin IIUbiquitin ThiolesteraseUSP10 protein, humanUSP10 protein, mouseArrhythmiasCardiologyCardiovascular diseaseUbiquitin-proteosome systemVascular biology

Identifiers

PMID42635049
PMCPMC13502181

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.